Arrowstreet Capital, Limited Partnership Blueprint Medicines Corp Transaction History

Arrowstreet Capital, Limited Partnership

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$48.11 - $82.22 $2.89 Million - $4.93 Million	-59,988 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$66.73 - $82.59 $4 Million - $4.95 Million	59,988 New	59,988 $4.81 Million
Q3 2018 Nov 14, 2018	SELL	$58.91 - $78.32 $913,517 - $1.21 Million	-15,507 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$60.96 - $101.18 $945,306 - $1.57 Million	15,507 New	15,507 $984,000
Q1 2018 May 14, 2018	SELL	$73.28 - $102.95 $227,168 - $319,145	-3,100 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$62.91 - $88.32 $195,021 - $273,792	3,100	3,100 $234,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.